Nexstim Plc ends negotiations with potential chinese partner

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announces that it has ended its on-going negotiations with a potential Chinese partner for the assembly and distribution of its products in China. 

Nexstim announced on 16 October 2017 that it was negotiating with a potential Chinese partner. The assembly and distribution agreement that was under discussionincluded a potential equity investment in Nexstim of up to EUR 1 million as well as a loan grant of EUR 1 million.

Nexstim intends to begin a new search for a partner to help its products gain access to the Chinese market.

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

About Nexstim Plc

Nexstim is a targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBT® system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBT® system for this important indication during Q2 2018.

The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

Media contact

Citigate Dewe Rogerson

David Dible / Isabelle Andrews / Shabnam Bashir
3 London Wall Buildings
London Wall
London
EC2M 5SY

Tel: +44 (0) 207 2822949
Nexstimcitigatedewerogersoncom